Eli Lilly And Company
$1.09T- Market cap
- $1.06T
- Debt
- +$42.50B
- Cash
- −$7.27B
Capital structure 96% equity / 4% debt · EV / Revenue 16.76x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $1.06T · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: LLY stock price at discount vs ABBV $1.12K current versus $2.48K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABBV's multiple
Implied fair value · at LLY's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Multiple premium
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 96% equity / 4% debt · EV / Revenue 16.76x
Capital structure 87% equity / 13% debt · EV / Revenue 8.35x · EV proxy / EBITDA proxy 21.99x
LLY carries the larger enterprise value at $1.09T against $510.38B; ABBV trades on the lower EV / Revenue multiple (8.35x vs 16.76x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
AbbVie Inc. · implied price per share
Bear
$87.89
Base
$110.94
Bull
$142.98
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LLY can sustain its 44.7% revenue growth and 31.7% net margin, then holding or adding on weakness is reasonable because the premium valuation is being backed by materially stronger fundamentals than ABBV.
LLY trades at a much higher absolute valuation than ABBV on sales and EBITDA measures, but the P/E gap is narrower because ABBV’s earnings multiple is elevated. LLY also sits near the upper end of its historical band, suggesting the stock is already pricing in a lot of operational strength.
Supporting Metrics